Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(4.31)
# 413
Out of 5,113 analysts
55
Total ratings
35.71%
Success rate
43.98%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $21.92 | +237.59% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $7.76 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $63.96 | +37.59% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $17.82 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $43.90 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $72.34 | +32.71% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $9.21 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $220.80 | - | 2 | Jun 10, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $10.27 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $11.29 | - | 4 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $17.60 | -26.08% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.73 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $55.86 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $102.69 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $24.46 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.52 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $36.01 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $174.80 | +67.05% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $456.20 | -18.90% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.34 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.47 | - | 1 | May 30, 2017 |
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $21.92
Upside: +237.59%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $7.76
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $63.96
Upside: +37.59%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $17.82
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $43.90
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $72.34
Upside: +32.71%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $9.21
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $220.80
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.27
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $11.29
Upside: -
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $17.60
Upside: -26.08%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.73
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $55.86
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $102.69
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $24.46
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.52
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.01
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $174.80
Upside: +67.05%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $456.20
Upside: -18.90%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.34
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.47
Upside: -